Wegovy and heart health: what the clinical evidence actually shows

Why Wegovy carries a heart-protection licence alongside its weight-loss one

A question our prescribers hear most weeks is whether Wegovy is actually safe for someone who already has heart disease, or whether the concern should go the other way and the medicine might help. The short answer is that, for a specific group, it appears to help significantly.

The SELECT trial, one of the largest cardiovascular outcomes studies run for any weight-loss medicine, followed 17,604 adults with pre-existing cardiovascular disease and a BMI of 27 or above, none of whom had type 2 diabetes at enrolment. Over roughly five years, those taking semaglutide 2.4 mg weekly saw around a 20% reduction in the combined risk of heart attack, non-fatal stroke and cardiovascular death compared with placebo. The result was striking enough that the MHRA granted Wegovy a standalone UK authorisation for cardiovascular risk reduction, separate from and in addition to its weight-management licence. You can read the full regulatory position in the NHS overview of semaglutide, which covers both authorised uses.

What the trial cannot tell us is which individual will benefit and by how much. The protective signal was measured across a large population; your own cardiovascular history, blood pressure, kidney function and other medicines all influence whether this treatment is suitable. That clinical picture is precisely what a prescriber works through before approving anything. If you are exploring what Wegovy's heart-health evidence means in practice, that page goes deeper into the mechanisms behind the SELECT findings, and you can also find a detailed look at how semaglutide affects the heart across the range of people who use it.

Heart rate changes: a different issue from cardiovascular protection

It is worth separating two distinct heart-related topics that often get folded together. The cardiovascular outcome data above describes protection against serious events like heart attack and stroke. Heart rate is a separate, physiological effect observed during treatment.

GLP-1 receptor agonists including semaglutide can increase resting heart rate modestly, typically by around one to four beats per minute on average across trial populations, though individual responses vary. For most people this is clinically insignificant and settles with time. For someone with a pre-existing arrhythmia or another condition sensitive to heart rate, it is something a prescriber specifically considers before and during treatment. This is not a reason to avoid treatment across the board; it is one of the factors that makes clinical review before prescribing genuinely important rather than a formality. If you want detail on this specific effect, the page on Wegovy and heart rate covers what the data shows and what to watch for, and our page on semaglutide and heart rate explores the underlying pharmacology in more depth.

The MHRA's guidance on GLP-1 medicines for weight loss, published on GOV.UK, is clear that these medicines should be used within proper clinical oversight, not purchased informally or without a full medical assessment.

Making the decision: what your prescriber is actually weighing up

If you are trying to decide whether Wegovy is a reasonable option given your cardiovascular history, the decision is not binary. It sits inside a fuller clinical picture that includes your weight, any existing conditions, your current medicines, and what your goals actually are.

For people who meet the cardiovascular-indication criteria (overweight or obese with confirmed heart disease), the evidence suggests treatment may offer meaningful protection beyond weight loss alone. For people who want to use Wegovy primarily for weight management and happen to have a heart condition in their background, the prescriber considers tolerability, interactions with cardiac medicines, and any heart-rate sensitivity. The overview of Wegovy and specific heart conditions covers scenarios where that clinical picture varies most.

Wegovy is not suitable during pregnancy, and the safety of treatment must be assessed against your full medical history. Prescribers at a service like ours review every application personally rather than running it through a screening algorithm. That matters most when the health picture is genuinely complex. On the question of cost, the Wegovy price page explains what a legitimate private prescription includes, which is worth reading if you are comparing services. And if you want to understand the broader treatment landscape before committing to anything, our treatment overview sets out the options clearly.

The right place to start, if you have cardiovascular history and are curious about semaglutide, is a proper consultation. The evidence is encouraging; the individual decision is a clinical one.

When you are ready, you can start your free consultation with our prescribers.